Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer

Supportive Care in Cancer

Volumn 22, Issue 1, 2014, Pages 103-113

  Hagiwara, May ^a   Delea, Thomas E ^a   Cong, Ze ^b   Chung, Karen ^b  

^a POLICY ANALYSIS INC PAI   (United States)

^b AMGEN INC   (United States)

Author keywords

Bone metastases; Healthcare utilization; Intravenous bisphosphonates; Solid tumor

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CRIZOTINIB; ERLOTINIB; GEFITINIB; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LAPATINIB; OPIATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRASTUZUMAB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HYPERCALCEMIA; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ORCHIECTOMY; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; SPINAL CORD COMPRESSION; UNITED STATES;

EID: 84890547683     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1951-z     Document Type: Article

References (16)

1. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588-1594
2. Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 129:495-503
3. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162-167
4. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group J Clin Oncol 16:593-602
5. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group N Engl J Med 334:488-493
6. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
7. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822
8. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619
9. Hagiwara M, Delea TE, Saville MW, Chung K (2013) Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 16:23-27
10. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) A note on competing risks in survival data analysis. Br J Cancer 91:1229-1235
11. Bergstralh E (2008) Locally Written SAS Macros. Division of Biomedical Statistics and Informatics. Mayo Clinic http://mayoresearch.mayo.edu/mayo/ research/biostat/sasmacros.cfm. Accessed 27 March 2013
12. Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Barber B, Oster G (2011) Healthcare costs in patients with metastatic lung cancer receiving chemotherapy BMC health services research 11: 305
13. Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Qin A, Oster G (2011) Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC cancer 11:250
14. Novartis Pharmaceuticals Corporation (2012) Zometa® (zoledronic acid) Prescribing Information. November 2012 http://www.pharma.us.novartis.com/ product/pi/pdf/Zometa.pdf. Accessed 21 March 2013
15. Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2008) Use of intravenous bisphosphonates in older women with breast cancer. The oncologist 13:494-502
16. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A (2008) Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 113:1438-1445